Movement Alert｜Tempus AI Rises 5.07% in Regular Trading, Boosted by Extended Recursion Data License and RNA Model Authorization

Market Focus09-24 22:15

On September 24, Tempus AI rose 5.07% in regular trading, trading at approximately $80.54 per share, with turnover of $2.31 billion. The rally was driven by the company's announcement of an extended data license agreement with Recursion Pharmaceuticals and a new RNA model authorization deal.

Specifically, Tempus AI extended its data license agreement with Recursion through November 2029 and revised the fee structure — replacing up to $84 million in discretionary payments over two years with $42 million in committed payments over three years. Separately, Tempus signed an agreement granting it a nonexclusive, worldwide license to Recursion's proprietary RNA sequencing foundation model, further enriching its multimodal data capabilities and strengthening its precision medicine algorithmic edge.

Broader sector strength also provided support. Within the Life Sciences Tools & Services sector, Illumina rose 4.15%, Agilent gained 4.19%, Waters climbed 3.45%, Thermo Fisher Scientific added 2.19%, and Danaher advanced 2.03%, reflecting broad-based positive sentiment across the industry.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1176848124?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-24 22:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1176848124","market":"us","top_or_hot":-1,"title":"Movement Alert｜Tempus AI Rises 5.07% in Regular Trading, Boosted by Extended Recursion Data License and RNA Model Authorization","media":"Market Focus","content":"<p><p>On September 24, Tempus AI rose 5.07% in regular trading, trading at approximately $80.54 per share, with turnover of $2.31 billion. The rally was driven by the company's announcement of an extended data license agreement with Recursion Pharmaceuticals and a new RNA model authorization deal.</p><p>Specifically, Tempus AI extended its data license agreement with Recursion through November 2029 and revised the fee structure — replacing up to $84 million in discretionary payments over two years with $42 million in committed payments over three years. Separately, Tempus signed an agreement granting it a nonexclusive, worldwide license to Recursion's proprietary RNA sequencing foundation model, further enriching its multimodal data capabilities and strengthening its precision medicine algorithmic edge.</p><p>Broader sector strength also provided support. Within the Life Sciences Tools & Services sector, Illumina rose 4.15%, Agilent gained 4.19%, Waters climbed 3.45%, Thermo Fisher Scientific added 2.19%, and Danaher advanced 2.03%, reflecting broad-based positive sentiment across the industry.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Tempus AI Rises 5.07% in Regular Trading, Boosted by Extended Recursion Data License and RNA Model Authorization</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Tempus AI Rises 5.07% in Regular Trading, Boosted by Extended Recursion Data License and RNA Model Authorization\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-09-24 22:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On September 24, Tempus AI rose 5.07% in regular trading, trading at approximately $80.54 per share, with turnover of $2.31 billion. The rally was driven by the company's announcement of an extended data license agreement with Recursion Pharmaceuticals and a new RNA model authorization deal.</p><p>Specifically, Tempus AI extended its data license agreement with Recursion through November 2029 and revised the fee structure — replacing up to $84 million in discretionary payments over two years with $42 million in committed payments over three years. Separately, Tempus signed an agreement granting it a nonexclusive, worldwide license to Recursion's proprietary RNA sequencing foundation model, further enriching its multimodal data capabilities and strengthening its precision medicine algorithmic edge.</p><p>Broader sector strength also provided support. Within the Life Sciences Tools & Services sector, Illumina rose 4.15%, Agilent gained 4.19%, Waters climbed 3.45%, Thermo Fisher Scientific added 2.19%, and Danaher advanced 2.03%, reflecting broad-based positive sentiment across the industry.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TEM","symbol_name":"Tempus AI","start_time":0,"source_url":"","article_id":"1176848124","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1176848124","pubTimestamp":1790259339,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On September 24, Tempus AI rose 5.07% in regular trading, trading at approximately $80.54 per share, with turnover of $2.31 billion. The rally was driven by the company's announcement of an extended...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TEM":"Tempus AI"},"translate_title":"动向提醒|Tempus AI在常规交易中上涨5.07%，受递归数据许可和RNA模型授权的提振","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TEM":1},"content_text":"On September 24, Tempus AI rose 5.07% in regular trading, trading at approximately $80.54 per share, with turnover of $2.31 billion. The rally was driven by the company's announcement of an extended data license agreement with Recursion Pharmaceuticals and a new RNA model authorization deal.Specifically, Tempus AI extended its data license agreement with Recursion through November 2029 and revised the fee structure — replacing up to $84 million in discretionary payments over two years with $42 million in committed payments over three years. Separately, Tempus signed an agreement granting it a nonexclusive, worldwide license to Recursion's proprietary RNA sequencing foundation model, further enriching its multimodal data capabilities and strengthening its precision medicine algorithmic edge.Broader sector strength also provided support. Within the Life Sciences Tools & Services sector, Illumina rose 4.15%, Agilent gained 4.19%, Waters climbed 3.45%, Thermo Fisher Scientific added 2.19%, and Danaher advanced 2.03%, reflecting broad-based positive sentiment across the industry.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1176848124","isCrawlerRequest":true}